Position in EXEL
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$414,440
+$82,257 QoQ
Shares Held
7,617
-1.7% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#464
of 751 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rossby Financial, LCC holds $1,248,932 across 52 Biotechnology names. EXEL ranks #1 (33.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
7,617 | $414,440 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
242 | $150,896 | |
| 3 | INSM |
INSMED Inc
|
1,029 | $109,711 | |
| 4 | GMAB |
Genmab A/S
|
3,618 | $99,386 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
189 | $93,881 | |
| 6 | ARGX |
Argenx SE
|
74 | $68,654 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
136 | $40,940 | |
| 8 | URGN |
UroGen Pharma Ltd.
|
770 | $28,336 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $414,440 | 7,617 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $332,183 | 7,745 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $301,331 | 6,875 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $281,666 | 6,820 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $130,036 | 2,950 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $107,474 | 2,911 | Shares | Sole | 2025-04-28 | |
| No filing history on record for this holder in this stock. | ||||||